Company intelligence / Profile preview

KALSIOM

Ownership: Private
Development stage: Preclinical

Overview

KALSIOM is developing first-in-class monoclonal antibody therapies that modulate calcium signaling in B-cells for the treatment of autoimmune diseases. The company is based on over 15 years of academic research and has completed its first €2 million fundraising round to support preclinical development. No clinical results have been published yet.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodies
Industry: Biotech

Partnerships

SATT Ouest Valorisation (technology transfer and funding partner)GO CAPITAL, Advent France Biotechnology (investors/early-stage partners)

Beyond the preview

Go deeper on KALSIOM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KALSIOM.

Explore the full profile